Results 101 to 110 of about 8,787,182 (356)

Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocol

Cost Effectiveness and Resource Allocation, 2023
Background U.S. cost-effectiveness recommendations suggest that analyses should include all costs and effects relevant to the decision problem [1]. However, in many diseases, including spinal muscular atrophy (SMA), few studies have evaluated bereaved ...
Abigail G. Riley, Christina M. Mulé, Debra Lerner, Lisa Belter, Colleen McCarthy O’Toole, Stacey Kowal, David Fox, Sheila Shapouri, Tamara Vesel, Tara A. Lavelle   +9 more
doaj   +1 more source

Cost-Effectiveness Analysis

, 2017
Economic evaluation of healthcare programs seeks to compare treatments and preventive measures in terms of their efficiency, that is, their ability to generate health and well-being relative to the costs incurred. This chapter provides an introduction to one particular but widely used evaluation technique: cost-effectiveness analysis (CEA).
Luyten, Jeroen, Henderson, Cate
openaire   +3 more sources

Technologies to Support Community-Dwelling Persons With Dementia: A Position Paper on Issues Regarding Development, Usability, Effectiveness and Cost-Effectiveness, Deployment, and Ethics

JMIR Rehabilitation and Assistive Technologies, 2017
Background With the expected increase in the numbers of persons with dementia, providing timely, adequate, and affordable care and support is challenging.
F. Meiland, A. Innes, G. Mountain, L. Robinson, H. G. Van der Roest, J. A. García-Casal, D. Gove, J. R. Thyrian, S. Evans, R. Dröes, Fiona Kelly, A. Kurz, Dympna Casey, D. Szcześniak, T. Dening, Michael P. Craven, M. Span, Heike Felzmann, M. Tsolaki, M. Franco-Martin   +19 more
semanticscholar   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer

JAMA Oncology, 2018
Importance The age-based or “one-size-fits-all” breast screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at the cost of overdiagnosis.
N. Pashayan, S. Morris, F. Gilbert, P. Pharoah   +3 more
semanticscholar   +1 more source

Cost-effectiveness of managing Natura 2000 sites: an exploratory study for Finland, Germany, the Netherlands and Poland [PDF]

, 2010
Natura 2000 sites are expected to assure the long-term survival of Europe's most valuable and threatened species and habitats. It follows that successful management of the sites is of great importance.
Apeldoorn, R.C., van, Chmielewski, T., Kosola, M.L., Mewes, M., Varjopuro, R., Veeneklaas, F.R., Wätzold, F.   +6 more
core   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]

, 2011
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van, Joore, M.A., Retèl, Valesca P., Rutgers, E.J.Th.   +3 more
core   +1 more source

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. [PDF]

, 2014
BackgroundCurrent treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy.
Beca, Jaclyn, Bell, Chaim M, Bremner, Karen E, Crump, Michael, Gavura, Scott, Hoch, Jeffrey S, Hodgson, David, Khor, Sara, Krahn, Murray, Lee, Linda, Luo, Jin, Mamdani, Muhammad, Peacock, Stuart, Sawka, Carol, Sullivan, Terrence, Trudeau, Maureen   +15 more
core   +2 more sources

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source